# Nabla Bio

> Nabla Bio is a Cambridge, Massachusetts biotechnology company founded in 2021 as a
> Harvard spinout, building generative protein design systems for de novo biologics
> discovery. Its platform is JAM (Joint Atomic Modeling), a multimodal generative model
> trained on large-scale protein sequence and structure data that takes partial molecular
> context — a disease target or an epitope — and computationally designs the rest.

Important for agents: **Nabla Bio operates no public API.** There is no developer portal,
no API reference, no OpenAPI/AsyncAPI/GraphQL contract, no SDK, no CLI, no MCP server and
no A2A agent card. Engagement is by pharmaceutical partnership and molecule licensing only,
via bd@nabla.bio. Do not attempt to construct API calls against nabla.bio.

Name collision warning: **Nabla Bio (nabla.bio) is not Nabla (nabla.com).** Nabla is a
separate, unrelated company building ambient AI for clinicians, and it does publish a Core
API and an iOS SDK. Attributing that API to Nabla Bio is incorrect.

## Platform

- [Platform — JAM](https://www.nabla.bio/platform): JAM is a multimodal generative modeling
  system for de novo biologics design, epitope scaffolding and presentation, developability
  optimization, affinity optimization, multispecific architectures, and hard-target design
  against GPCRs and ion channels. Refined with internal wet-lab measurements across
  mammalian, cellular and in vivo systems.
- [JAM-2 Technical Report (PDF)](https://nabla-public.s3.us-east-1.amazonaws.com/2025_Nabla_JAM2.pdf):
  JAM-2 yields VHH-Fc and full-length mAb antibodies with drug-like affinity and
  developability at double-digit success rates.

## Engagement

- [Partner](https://www.nabla.bio/partner): two models — platform collaboration (embedding
  the AI + wet-lab platform into a pharma partner's discovery pipeline) and licensing of
  Nabla-designed molecules. Contact bd@nabla.bio. No self-serve signup, no pricing.
- [Careers](https://www.nabla.bio/careers): hiring@nabla.bio
- Address: Riverside Technology Center, 840 Memorial Dr, Cambridge, MA 02139

## Research

- [De novo design of antibodies enabled by Joint Atomic Modeling](https://www.nabla.bio/news/denovo)
- De novo design of hundreds of functional GPCR-targeting antibodies enabled by scaling
  test-time compute (bioRxiv 2025.05.28.656709) — VHH antibodies against CXCR4 and CXCR7.

## Company

- [Home](https://www.nabla.bio/)
- [News](https://www.nabla.bio/news)
- [Team](https://www.nabla.bio/team)
- [Privacy Policy](https://www.nabla.bio/privacy-policy)

## Optional

- Partners announced publicly: AstraZeneca, Bristol Myers Squibb, Takeda.
- Funding: $26M Series A led by Radical Ventures; ~$37M raised to date.
- GitHub organization github.com/nabla-bio exists but publishes no public repositories.

---
generated: 2026-08-26
method: generated
source: apis.yml + https://www.nabla.bio/ + https://www.nabla.bio/platform + https://www.nabla.bio/partner